Prof Domenica Lorusso speaks to ecancer at ESMO 2023 about the randomised, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study which looked at using pembrolizumab plus chemoradiotherapy to treat high-risk locally advanced cervical cancer patients.

Eligible patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer were randomised 1:1 to receive 5 cycles of pembrolizumab 200 mg or pbo Q3W + concurrent chemoradiotherapy, then 15 cycles of pembrolizumab 400 mg or pbo Q6W.

The results demonstrated pembrolizumab plus concurrent chemoradiotherapy showed a statistically significant and clinically meaningful improvement in progression free survival and a favourable trend in overall survival compared with pbo plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer and had a manageable safety profile.